Intralesional rituximab for cutaneous B-cell lymphoma

British Journal of Dermatology

Volumn 144, Issue 6, 2001, Pages 1239-1243

  Paul, T ^a   Radny, P ^a   Krober S M ^b   Paul, A ^a   Blaheta, H J ^a   Garbe, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cutaneous B cell lymphoma; Intralesional therapy; Rituximab

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LYMPHOMA, B-CELL; MALE; PILOT PROJECTS; SKIN NEOPLASMS;

EID: 0035726343     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04241.x     Document Type: Article

References (25)

1. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
2. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
3. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
4. A unique cell surface antigen identifying lymphoid malignancies of B cell origin
5. The effect of rituximab on patients with follicular and mantle-cell lymphoma
6. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
7. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
8. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
9. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
10. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
11. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
12. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
13. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
14. Die therapie der primären kutanen B-zell-lymphome
15. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type
16. Primary B-cell lymphomas of the skin
17. Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases
18. Diffuse large cell lymphomas of follicular center cell origin presenting in the skin. A clinicopathologic and immunologic study of 16 patients
19. Radiotherapy of cutaneous B cell lymphomas: Our experience in 31 cases
20. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy
21. Cutaneous lymphomas other than mycosis fungoides: Follow-up study of 52 patients
22. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma
23. Borrelia burgdorferi-associated cutaneous B cell lymphoma: Clinical and immunohistologic characterization of four cases
24. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a
25. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma